Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP-1929 photoimmunotherapy versus physician's choice standard of care in recurrent head and neck squamous cell carcinoma
2018-002513-36Phase 3Terminated
- Sponsor
- Rakuten Medical, Inc.
- Start
- Apr 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing ASP-1929 photoimmunotherapy monotherapy with Physician's choice standard of care (2 arms). Primary endpoint: Progression-free survival. Started Apr 2019; status: terminated.
02
Drugs
cetuximab sarotalocan sodium
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2018-002513-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002513-36.